IDEAYA Biosciences (IDYA) Accounts Payables (2018 - 2026)

IDEAYA Biosciences has disclosed Accounts Payables across 9 years of filings, most recently posting $20.7 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $20.7 million, up 17.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.7 million (up 17.61% YoY), and the FY2025 annual result was $17.6 million, up 14.03% from the prior year.
• Accounts Payables came in at $20.7 million for Q1 2026 at IDEAYA Biosciences, up from $17.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $20.7 million in Q1 2026 to a low of $3.4 million in Q1 2022.
• The 5-year median for Accounts Payables is $6.6 million (2023), against an average of $10.5 million.
• Peak annual rise in Accounts Payables reached 180.3% in 2025, while the deepest fall reached 8.71% in 2025.
• IDEAYA Biosciences' Accounts Payables stood at $4.3 million in 2022, then soared by 54.16% to $6.6 million in 2023, then surged by 133.72% to $15.4 million in 2024, then increased by 14.03% to $17.6 million in 2025, then climbed by 17.93% to $20.7 million in 2026.
• The last three Accounts Payables figures came in at $20.7 million (Q1 2026), $17.6 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.